



Article Effect of Electrolyte Concentration on Cell Sensing by Measuring Ionic Current Waveform through Micropores

Kazumichi Yokota ¹, Muneaki Hashimoto ¹, Kazuaki Kajimoto ¹, Masato Tanaka ¹, Sanae Murayama ², Makusu Tsutsui ², Yoshihiro Nakajima ¹, Masateru Taniguchi ² and Masatoshi Kataoka ^{1,*}

- ¹ National Institute of Advanced Industrial Science and Technology, Takamatsu, Kagawa 761-0395, Japan; kazumichi-yokota@aist.go.jp (K.Y.); muneaki-hashimoto@aist.go.jp (M.H.); k-kajimoto@aist.go.jp (K.K.); mst-tanaka@aist.go.jp (M.T.); y-nakajima@aist.go.jp (Y.N.)
- ² The Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan; murayama@sanken.osaka-u.ac.jp (S.M.); tsutsui@sanken.osaka-u.ac.jp (M.T.); taniguti@sanken.osaka-u.ac.jp (M.T.)
- * Correspondence: m-kataoka@aist.go.jp; Tel.: +81-87-869-3576

Abstract: Immunostaining has been widely used in cancer prognosis for the quantitative detection of cancer cells present in the bloodstream. However, conventional detection methods based on the target membrane protein expression exhibit the risk of missing cancer cells owing to variable protein expressions. In this study, the resistive pulse method (RPM) was employed to discriminate between cultured cancer cells (NCI-H1650) and T lymphoblastoid leukemia cells (CCRF-CEM) by measuring the ionic current response of cells flowing through a micro-space. The height and shape of a pulse signal were used for the simultaneous measurement of size, deformability, and surface charge of individual cells. An accurate discrimination of cancer cells could not be obtained using $1.0 \times$ phosphate-buffered saline (PBS) as an electrolyte solution to compare the size measurements by a microscopic observation. However, an accurate discrimination of cancer cells with a discrimination error rate of $4.5 \pm 0.5\%$ was achieved using $0.5 \times$ PBS containing 2.77% glucose as the electrolyte solution. The potential application of RPM for the accurate discrimination of cancer cells from leukocytes was demonstrated through the measurement of the individual cell size, deformability, and surface charge in a solution with a low electrolyte concentration.

Keywords: resistive pulse method; cell discrimination; cancer cell; leukocyte; micropore

1. Introduction

The resistive pulse method (RPM), which is used to evaluate the transient ionic current blockade associated with the translocation of an individual nano- to micro-sized particle passing through a pore, can probe small objects as pulse-like electrical signals. These objects can be discriminated at a single-particle resolution because the measured ionic current blockade signals possess information regarding the physical properties of these particles, such as size [1], shape [2–4], surface charge [1,5], and deformability [6,7]. This technology is utilized for the discrimination of single-bioparticles of various sizes, ranging from blood cells to polynucleotides, without implementing immunostaining [2,8–10]. Micropore devices with micro-sized pores are mainly used for counting the number of cells and measuring their size [11]. They are used in hematological diagnosis to measure the number of blood cells, which is indicated by a Coulter counter.

The detection of rare cells in blood such as circulating tumor cells (CTCs), as well as counting the number of cells, is useful for clinical diagnosis [12]. CTCs are recovered from blood by centrifugation into leukocyte fraction, which can predict metastasis and determine drug efficacy. Although the identification of cancer cells from leukocytes at the single-cell level for the quantitative detection of CTCs focusing on biological properties with immunostaining has been put into practical use as a CellSearch system, cancer cells may be



Citation: Yokota, K.; Hashimoto, M.; Kajimoto, K.; Tanaka, M.; Murayama, S.; Tsutsui, M.; Nakajima, Y.; Taniguchi, M.; Kataoka, M. Effect of Electrolyte Concentration on Cell Sensing by Measuring Ionic Current Waveform through Micropores. *Biosensors* **2021**, *11*, 78. https:// doi.org/10.3390/bios11030078

Received: 18 February 2021 Accepted: 11 March 2021 Published: 12 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). overlooked when the antigen expression is low [13,14]. Meanwhile, several methods for distinguishing leukocytes from cancer cells focusing on physical characteristics such as cell size, which does not depend on immunostaining, have been reported; however, an accurate discrimination is difficult [15]. Therefore, by changing the measurement conditions (such as the electrolyte concentration) when taking measurements using the micropore device, the accuracy of cell discrimination was improved owing to the difference in cell deformability and surface charge in addition to the difference in size. In this study, we demonstrate the accuracy of the RPM in distinguishing cancer cells from leukocytes.

2. Materials and Methods

2.1. Cell Cultures and Sample Preparation for Measuring Ionic Current

Human bronchioalveolar carcinoma cells (NCI-H1650) were cultured in Rosewell Park Memorial Institute media 1640 (Nacalai Tesque, Kyoto, Japan) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin–streptomycin (GIBCO, Thermo Fisher Scientific Inc., Waltham, MA, USA), and 250 ng/mL Fungizone (GIBCO), and were subsequently harvested by centrifugation in trypsin. Human T lymphoblastoid leukemia cells (CCRF-CEM) were also cultured in a similar medium and harvested by centrifugation. Human gastric signet ring cell adenoma cancer cells (KATO-III) as other cancer cells were cultured in Iscove's modified Dulbeco's medium with L-glutamine and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Nacalai Tesque) containing 20% FBS, 100 U/mL penicillin–streptomycin, and 250 ng/mL Fungizone, and were subsequently harvested by centrifugation in trypsin. To prepare the cell samples for ionic current measurements, we prepared cell suspensions of 1×10^7 cells/mL in 1.0 × phosphate-buffered saline (PBS) and 0.5 × PBS containing 2.77% (w/v) glucose (Nacalai Tesque) (0.5 × PBS). Glucose was used to maintain the isotonic condition.

2.2. Fabrication of Microfluidic Cell Sensing Chips

The molds of the microchannels (17 μ m in height) with constrictions (17 μ m in width and 12 µm in length at the narrowest region) were formed with SU-8 photoresist (KAYAKU Advanced Materials, Inc. Tokyo, Japan) on a SiO₂/Si wafer (Electronics and Materials Co. Ltd., Hyogo, Japan) using a conventional photolithography method [16]. The constriction sizes were chosen to have the smallest value that prevents the cells from getting stuck in the constriction (data not shown). The base and curing agents were mixed at a ratio of 10:1, and then polydimethyl siloxane (PDMS; SILPOT 184, Dow Corning Toray Co., Ltd., Tokyo, Japan) was poured on top of the mold, which was surrounded by 17 mm imes 17 mm frames, and was cured at 100 °C for 35 min to fabricate a PDMS replica block. A block of PDMS replica was peeled from the mold, and 2 through-holes connecting the microchannel were punched out as the inlet and outlet for the samples. Each hole had a stainless-steel reservoir (Wurth Elektronik, Waldenburg, Germany) with an inner diameter of 3.0 mm. The fabricated block was bonded on a slide glass plate by activating both sides of the adhering surface through oxygen plasma exposure for 15 s under a 4 Pa pressure at 100 W (SC-708, Sanyu Electron Co., Ltd., Tokyo, Japan). The hydrophilizing agent poly(2-methacryloyloxylethyl phosphorylcholine (MPC)-co-2-ethylhexyl methacrylate (EHMA)-co-2-(N,N-dimethylamino)ethyl methacrylate (DAEMA)-co-poly(ethylene glycol) methacrylate (PEGMA) [17,18], named poly-(MPC-co-EHMA-co-DAEMA-co-PEGMA), was first injected through the inlet and then washed using water. Schematic illustrations of the microfluidic cell sensing chip are shown in Figure 1.



Figure 1. Microfluidic cell sensing chip. (a) Picture of microfluidic cell sensing chip made of polydimethyl siloxane (PDMS) fabricated on a slide glass. (b) Design of the mold used for the SU-8 microchannel. One constriction operating as a narrow flow path was formed. The microchannel was formed at the bottom of a replicated PDMS and sealed using a slide glass. The cell samples in $1.0 \times$ phosphate-buffered saline (PBS) or $0.5 \times$ PBS were injected from the inlet through a hole connecting the microchannel until it was full. For each analysis, 7 µL of electrolyte solution was added to the inlet reservoir to apply a pressure of 10 Pa. (c) Schematic illustration of ionic current blockade by resistive pulse method (RPM). Each constriction was 17 µm in width, 12 µm in length, and 17 µm in height. The translocation of cells through a constriction generated a pulse-like ionic current blockade, and electrical signals were then measured as a source measurement unit (SMU). The translocation of cells can be simultaneously observed using inverse optical microscopy.

The microchannel in the fabricated chip possessed one constriction that was 17 μ m in width, 12 μ m in length, and 17 μ m in height at the narrowest region for measuring the transient ionic current blockade by RPM (Figure 1b,c). An inverse optical microscope was installed at the constriction to observe the translocation of cells through the channel.

2.3. Cell Size Measurement by Using Optical Microscope

To determine the size of cancer cells and leukocytes, we examined 100 cells in each cell suspension, namely, $1.0 \times PBS$ and $0.5 \times PBS$ containing 2.77% glucose, using an optical microscope (DIML II, Leica Camera AG, Wetzlar, Germany) with a 20 × objective lens. Approximately 20 µL of each cell sample was seeded into a 96-well plate (Nunc MicroWell 96-Well Microplates, Thermo Fisher Scientific Inc.) to settle at the bottom of the surface. The diameter of each cell was then measured immediately (Figure 2a–d); a histogram with a width of 0.5 µm was generated to evaluate the cell size distribution of each cell (Figure 2e,f).



Figure 2. Cell size analysis by light microscopy. The microscope images of (**a**) cancer cells in $1.0 \times \text{PBS}$, (**b**) leukocytes in $1.0 \times \text{PBS}$, (**c**) cancer cells in $0.5 \times \text{PBS}$, and (**d**) leukocytes in $0.5 \times \text{PBS}$. (**e**) Histograms of the size distribution obtained for each cell evaluated using the microscopic images. (**f**) The average values and standard deviation for the cell diameters. The size of leukocytes in $0.5 \times \text{PBS}$ is significantly smaller than that in $1.0 \times \text{PBS}$. A comparison between the two groups was performed using an unpaired *t*-test. The statistical significance is marked with * and a, b (p < 0.01).

2.4. Determination of Decision Boundary and Discrimination Error

A quadratic discrimination analysis (QDA) with the nonlinear separation boundary (Figures 2e and 3c,f) is able to discriminate the different classes more accurately than the linear separation boundary [19]. QDA is a probabilistic parametric classification technique. It separates the class region by quadratic boundaries and assumes that each class has a multivariate normal distribution, while the dispersion is different in the classes. The decision boundary (DB) by QDA for cell discrimination is defined by a contour line/curve providing an equal probability of the I_p , t_d , and I_p – t_d distribution for cancer cells and leukocytes [20,21]. The probability is expressed as follows:

$$P(y_i) = \frac{1}{\sqrt{|2\pi\Sigma_k|}} \exp\left(-\frac{1}{2}(y_i - \langle y \rangle_k)^T \Sigma_k^{-1}(y_i - \langle y \rangle_k)\right)$$
(1)

where Σ_k and $\langle y \rangle_k$ are the variance–covariance matrix and the mean value of observations y for parameters of the kth dimension, respectively. The discrimination error was calculated by cross-validation as $100 \times (FN + FP)/(TP + FN + FP + TN)$ [22]. Here, TP, FN, FP, and TN are the number of signals for true positive, false negative, false positive, and true negative cancer cells and white blood cells, respectively. The confidence interval (CI) for the discrimination error rate was evaluated using the Clopper–Pearson method [23].



Figure 3. Electric current measurement by RPM. A typical waveform of the ionic current blockade by RPM was observed for (**a**) a cancer cell and (**b**) leukocytes in $1.0 \times \text{PBS}$. (**c**) The histogram of I_p and t_d , scatter plot of I_p-t_d , and the decision boundary for these cells. A typical waveform of the ionic current blockade by RPM was observed for (**d**) a cancer cell and (**e**) leukocytes in $0.5 \times \text{PBS}$. (**f**) The histogram of I_p and t_d , scatter plot of I_p-t_d , and the DBs for these cells.

2.5. Ionic Current Measurements

Before performing the measurements, the microchannels of the fabricated device were filled with $1.0 \times PBS$ or $0.5 \times PBS$ as the electrolyte solution. Then, 10 μ L of cell samples corresponding to each electrolyte solution were injected through the inlet. For cell mixture measurement, each 5 μ L of cancer cell and leukocyte samples were mixed and injected. For each analysis, 7 μ L of the electrolyte solution was added to the inlet reservoir to apply a pressure of 10 Pa as a driving force for the cells to translocate into the microchamber from the inlet to the outlet. A pair of platinum ($\varphi = 0.8$ mm and 99.98 % purity, The Nilaco Corporation, Tokyo, Japan) electrodes coated with Ag/AgCl ink (ALS Co., Ltd., Tokyo, Japan) was then inserted through both the holes, each corresponding to the inlet and outlet. A bias voltage V_b was applied to the electrode at the outlet, while the inlet electrode was grounded. The ionic current was measured using a source measurement unit (SMU, NI PXIe-4141, National Instruments, Austin, TX, USA) at a current range of 10 μA with the LabVIEW (LabVIEW 2017, National Instruments) program. The time trace of the ionic current was evaluated via the constrictions and was recorded at a sampling rate of 50 kHz, which corresponds to a 20 µs resolution time. Typical wave forms of the ionic current blockade for cancer cells and leukocytes are shown in Figure 3a,b,d,e; the duration time of a current blockade signal was $>\approx 10$ ms and the employed sampling rate was sufficient to analyze each signal of the current blockade. Typical histograms are also shown in Figure 3c,f.

2.6. Resistive Pulse Analyses and Cell Discrimination

Resistive pulse signals that appeared on the time trace of the ionic current were searched by monitoring the current displacement, which was larger than the threshold by 3 times the standard deviation (SD). To reduce the current noise in the pulse search process, we averaged the data for 10 nearest neighboring points, as reported by Smeets et al. [24]. At the time point of pulse detection, the waveform of the pulses of the original 50 kHz data was extracted, and the baseline current level was offset to zero. The peak values of the

current blockade (I_p) and the duration time of the current blockades (t_d) were evaluated on the extracted waveform (Figure 3a,b). These data processes were conducted using the LabVIEW program.

2.7. Zeta Potential Measurements

In RPM, t_d can be utilized to elucidate the surface charge of the sensed particles [1,5]. The surface charge of cells can be estimated by examining the zeta potential [25,26]. A zeta potential analyzer (ELSZ-2000Z Otsuka Electronics Co., Ltd. Osaka, Japan) was used for the measurements in this study. A glass flow cell was filled with 1.0 mL of cell sample at a concentration of 2×10^8 cells/mL in $1.0 \times$ PBS and $0.5 \times$ PBS. While applying an electric field of ≈ 15 V/cm on average, we evaluated the electrical mobility from the doppler shift on the scattering light of the laser, and the zeta potential ζ was obtained by fitting the electrophoretic velocity of the cells flowing inside the measurement glass cell on the basis of the Smoluchowski equation [27].

3. Results and Discussion

3.1. Cell Size Examination by Light Microscopy

We employed cancer cells (NCI-H1650) that are relatively smaller compared to other cancer cells and overlap with leukocytes (CCRF-CEM) [15,28,29]. To examine the size of the cancer cells and leukocytes, we used light microscopy for the cell samples in $1.0 \times PBS$ or $0.5 \times PBS$. Light microscopic images of these cells are shown in Figure 2a–d, and the histograms of the size distribution for these cells are shown in Figure 2e. Although the cancer cells in $1.0 \times PBS$ were statistically discriminated from the leukocytes owing to their larger cell size (the average value and the SD for diameters of cancer cells were $12.5 \pm 2.5 \mu m$ and those for leukocytes were $9.8 \pm 1.0 \mu m$, p < 0.01), an overlap in the cell size was also observed in the histogram (Figure 2e,f). The decision boundary (DB) for the cell discrimination in terms of cell size was evaluated at $11.3 \mu m$, with a discrimination error of 17.5 % (Figure 2e, Table 1).

This result was similar to that of CTC isolation, which relies on the cell size exclusion loss from 20 to 50 % of CTCs [15]. The DB and the discrimination error rate in $0.5 \times PBS$ were 10.3 µm and 8.5%, respectively (Figure 2e, Table 1). The summarized mean value of each cell's diameter is shown in Figure 2f. The mechanism for the significant decrease in the size of the leukocytes when a solution with a low electrolyte concentration is used is unknown; despite maintaining the isotonicity condition by adding glucose, the size of the leukocytes in $0.5 \times PBS$ was approximately 7% smaller than that in $1.0 \times PBS$. When mannitol or sorbitol was used instead of glucose in $0.5 \times PBS$, we observed similar cell size decreases (data not shown); leukocyte cell size decrease was thought to be due to low salt stress. Therefore, the improvement in accuracy for cell discrimination in the solution with a low electrolyte concentration must have been due to the decrease in the size of leukocytes.

Table 1. Discrimination of cancer cells from leukocytes in terms of cell size using microscopic examination, and that on I_p , t_d , and I_p-t_d acquired by RPM.

| Discrimination Based on the Cell Size by a Microscopic Examination | | | | | | | |
|--|--------------------------|-------------------|--------|---------------|------------------|--------|--|
| | Predicted Classification | | | | | | |
| Actual Classification | $1.0 \times PBS$ | | | 0.5 	imes PBS | | | |
| | Cancer Cells | Leukocytes | ER (%) | Cancer Cells | Leukocytes | ER (%) | |
| Cancer cells | 71 (TP) | 29 (FN) | 17.5 | 90 (TP) | 10 (FN) | 8.5 | |
| Leukocytes | 6 (FP) | 94 (TN) | | 7 (FP) | 93 (TN) | | |
| Confidence interval of error rate (ER) | | 95% CI, 12.5–23.5 | | | 95% CI, 5.0–13.3 | | |

| Predicted Classification by I_p Actual Classification I.0 × PBS 0.5 × PBS Cancer Cells Leukocytes ER (%) Cancer Cells Leukocytes ER (%) Cancer cells 163 87 24.2 237 13 5.0 Cancer cells 140 110 20 230 20 5.4 Cancer cells 122 128 31.0 238 12 3.8 Cancer cells 122 128 31.0 7 243 3.8 Discrimination ER (mean \pm SD %, n = 3) 27.3 \pm 3.5 $4.7 \pm 0.8 **$ $4.7 \pm 0.8 **$ $4.7 \pm 0.8 **$ Actual Classification Predicted Classification by t_d $7.0 \pm 0.8 **$ $7.0 \pm 0.8 **$ Cancer cells 109 141 45.4 231 19 6.0 Cancer cells 96 154 44.8 224 26 7.0 Cancer cells 96 154 44.8 92 7.0 235 7.0 Leukocy | Discrimination Based on I_p , or t_d Acquired by RPM | | | | | | | |
|--|--|---|--------------|---|---------------|----------------|--------|--|
| Actual Classification $1.0 \times PBS$ $0.5 \times PBS$ Cancer Cells Leukocytes ER (%) Cancer Cells Leukocytes ER (%) Cancer cells 163 87 24.2 237 13 5.0 Cancer cells 140 110 26.6 7 243 5.4 Cancer cells 122 128 31.0 7 243 3.8 Cancer cells 122 128 31.0 7 243 3.8 Discrimination ER (mean \pm SD %, n = 3) 27.3 \pm 3.5 4.7 \pm 0.8 ** 4.7 \pm 0.8 ** 4.7 \pm 0.8 ** Cancer cells 109 141 45.4 231 19 6.0 Cancer cells 96 154 44.8 9 241 7.0 Leukocytes 70 180 44.8 9 241 7.0 Cancer cells 184 66 45.2 230 20 7.0 Leukocytes 160 90 45.1 \pm 0.3 6.7 \pm 0.6 ** 5.4 | | | | Predicted Classification by <i>I</i> _p | | | | |
| $\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$ | Actual Classification | 1.0 	imes PBS | | | 0.5 × PBS | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | Cancer Cells | Leukocytes | ER (%) | Cancer Cells | Leukocytes | ER (%) | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Cancer cells | 163 | 87 | 24.2 | 237 | 13 | 5.0 | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Leukocytes | 34 | 216 | 24.2 | 12 | 238 | 5.0 | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Cancer cells | 140 | 110 | 26.6 | 230 | 20 | 5.4 | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Leukocytes | 23 | 227 | 20.0 | 7 | 243 | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Cancer cells | 122 | 128 | 21.0 | 238 | 12 | 3.8 | |
| $\begin{array}{c c c c c c c c c } \hline Discrimination ER (mean \pm SD \%, n = 3) & 27.3 \pm 3.5 & 4.7 \pm 0.8 ** & \\ \hline \begin{tabular}{ c c c c c } \hline \begin{tabular}{ c c c c } \hline \begin{tabular}{ c c c c } \hline \begin{tabular}{ c c c } \hline \begin{tabular}{ c c c c } \hline \begin{tabular}{ c c c c } \hline \begin{tabular}{ c c c } \hline \begin{tabular}{ c c c } \hline \begin{tabular}{ c $ | Leukocytes | 27 | 223 | 51.0 | 7 | 243 | | |
| $\begin{tabular}{ c c c c c c c c c c } \hline Actual Classification & Predicted Classification by t_d \\ \hline Cancer cells & 109 & 141 & 45.4 & 231 & 19 & 6.0 \\ \hline Leukocytes & 86 & 164 & 45.4 & 11 & 239 & 6.0 \\ \hline Leukocytes & 86 & 164 & 45.4 & 11 & 239 & 6.0 \\ \hline Cancer cells & 96 & 154 & 44.8 & 9 & 241 & 7.0 \\ \hline Leukocytes & 70 & 180 & 44.8 & 9 & 241 & 7.0 \\ \hline Cancer cells & 184 & 66 & 45.2 & 230 & 20 & 7.0 \\ \hline Leukocytes & 160 & 90 & 45.2 & 15 & 235 & 7.0 \\ \hline Discrimination ER & 45.1 \pm 0.3 & 6.7 \pm 0.6 ** & \\ \hline \hline \hline \hline Discrimination Based on I_p-t_d Acquired by RPM & \\ \hline \hline \hline \hline Leukocytes & 1.0 \times PBS & 0.5 \times PBS & \\ \hline \hline Cancer cells & 202 & 48 & 14.2 & 238 & 12 & 4.6 \\ \hline Cancer cells & 203 & 227 & 14.2 & 11 & 239 & 4.6 \\ \hline \hline Cancer cells & 172 & 78 & 20.2 & 234 & 16 & 5.0 \\ \hline \hline Cancer cells & 172 & 78 & 20.2 & 234 & 16 & 5.0 \\ \hline \hline \end{array}$ | Discrimination ER (mean \pm SD %, <i>n</i> = 3) | 27.3 ± 3.5 4.7 ± 0.8 ** | | | | | | |
| $\begin{tabular}{ c c c c c c c c c c } \hline Cancer cells & 109 & 141 & 45.4 & 231 & 19 & 6.0 \\ \hline Leukocytes & 86 & 164 & 45.4 & 11 & 239 & 6.0 \\ \hline Cancer cells & 96 & 154 & 44.8 & 9 & 241 & 7.0 \\ \hline Leukocytes & 70 & 180 & 44.8 & 9 & 241 & 7.0 \\ \hline Cancer cells & 184 & 66 & 45.2 & 230 & 20 & 7.0 \\ \hline Leukocytes & 160 & 90 & 45.2 & 15 & 235 & 7.0 \\ \hline Discrimination ER & 45.1 \pm 0.3 & 6.7 \pm 0.6 ** & \hline \hline Discrimination Based on I_p-t_d Acquired by RPM & \hline \hline Predicted Classification by I_p-t_d & \hline \hline Actual Classification & I.0 \times PBS & 0.5 \times PBS & \hline \hline Cancer cells & Leukocytes & ER (%) & Cancer Cells & Leukocytes & ER (%) & Cancer Cells & Leukocytes & ER (%) & Cancer cells & 12 & 4.6 \\ \hline Cancer cells & 202 & 48 & 14.2 & 238 & 12 & 4.6 \\ \hline Cancer cells & 172 & 78 & 20.2 & 234 & 16 & 5.0 \\ \hline Cancer cells & 172 & 78 & 20.2 & 234 & 16 & 5.0 \\ \hline \end{tabular}$ | Actual Classification | Predicted Classification by t _d | | | | | | |
| $\begin{tabular}{ c c c c c c c c c c } \hline Leukocytes & 86 & 164 & 45.4 & 11 & 239 & 6.0 \\ \hline Cancer cells & 96 & 154 & 44.8 & 9 & 241 & 7.0 \\ \hline Leukocytes & 70 & 180 & 44.8 & 9 & 241 & 7.0 \\ \hline Cancer cells & 184 & 66 & 45.2 & 230 & 20 & 7.0 \\ \hline Leukocytes & 160 & 90 & 45.2 & 15 & 235 & 7.0 \\ \hline Discrimination ER & 45.1 \pm 0.3 & 6.7 \pm 0.6 ** & \hline \hline \hline Discrimination Based on I_p-t_d Acquired by RPM & \hline \hline \hline \hline Predicted Classification by I_p-t_d & \hline \hline I.0 \times PBS & 0.5 \times PBS & \hline \hline Cancer cells & Leukocytes & ER (%) & Cancer Cells & Leukocytes & ER (%) & Cancer Cells & Leukocytes & ER (%) & Cancer cells & 202 & 48 & 14.2 & 238 & 12 & 4.6 \\ \hline Cancer cells & 202 & 48 & 14.2 & 238 & 12 & 4.6 & \hline \hline Cancer cells & 172 & 78 & 20.2 & 234 & 16 & 5.0 & \hline \hline Leukocytes & 172 & 78 & 20.2 & 234 & 16 & 5.0 & \hline \hline \end{tabular}$ | Cancer cells | 109 | 141 | 141 | 231 | 19 | 6.0 | |
| $\begin{tabular}{ c c c c c c c c c c c } \hline Cancer cells & 96 & 154 & 44.8 & 224 & 26 & 7.0 \\ \hline Leukocytes & 70 & 180 & 44.8 & 9 & 241 & 7.0 \\ \hline Cancer cells & 184 & 66 & 45.2 & 230 & 20 & 7.0 \\ \hline Leukocytes & 160 & 90 & 45.2 & 15 & 235 & 7.0 \\ \hline Discrimination ER & 45.1 \pm 0.3 & 6.7 \pm 0.6 ** & & \\ \hline \hline \hline Discrimination Based on I_p-t_d Acquired by RPM & & & \\ \hline \hline \hline \hline \hline \\ \hline Cancer Cells & Leukocytes & ER (\%) & Cancer Cells & Leukocytes & ER (\%) \\ \hline Cancer cells & 202 & 48 & 14.2 & 238 & 12 & 4.6 \\ \hline Cancer cells & 202 & 48 & 14.2 & 11 & 239 & 4.6 \\ \hline Cancer cells & 172 & 78 & 20.2 & 234 & 16 & 5.0 \\ \hline \hline \hline \\ Cancer cells & 172 & 78 & 20.2 & 234 & 16 & 5.0 \\ \hline \hline \end{array}$ | Leukocytes | 86 | 164 | 45.4 | 11 | 239 | | |
| $\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$ | Cancer cells | 96 | 154 | 44.9 | 224 | 26 | 7.0 | |
| $\begin{tabular}{ c c c c c c c c c c } \hline Cancer cells & 184 & 66 & 45.2 & 230 & 20 & 7.0 \\ \hline Leukocytes & 160 & 90 & 45.2 & 15 & 235 & 7.0 \\ \hline Discrimination ER & 45.1 \pm 0.3 & 6.7 \pm 0.6 ** & & \\ \hline Discrimination Based on $I_{\rm p}$-t_{\rm d}$ Acquired by RPM & & & & \\ \hline \hline Discrimination Based on $I_{\rm p}$-t_{\rm d}$ Acquired by RPM & & & & \\ \hline \hline Leukocytes & 1.0 \times PBS & 0.5 \times PBS & & & \\ \hline \hline Cancer Cells & Leukocytes & ER (\%) & Cancer Cells & Leukocytes & ER (\%) \\ \hline Cancer cells & 202 & 48 & 14.2 & 238 & 12 & 4.6 \\ \hline Cancer cells & 23 & 227 & 14.2 & 11 & 239 & 4.6 \\ \hline Cancer cells & 172 & 78 & 20.2 & 234 & 16 & 5.0 \\ \hline \hline Cancer cells & 172 & 78 & 20.2 & 0 & 0 & 0 \\ \hline \hline Leukocytes & 20 & 2077 & 20.2 & 0 & 0 & 0 & 0 \\ \hline \hline Leukocytes & 20 & 2077 & 20.2 & 0 & 0 & 0 & 0 \\ \hline \hline \ Leukocytes & 20 & 2077 & 20.2 & 0 & 0 & 0 & 0 \\ \hline \hline \ \hline \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$ | Leukocytes | 70 | 180 | 44.8 | 9 | 241 | | |
| Leukocytes1609043.2152357.0Discrimination ER 45.1 ± 0.3 6.7 ± 0.6 **Discrimination Based on I_p-t_d Acquired by RPMPredicted Classification by I_p-t_d Actual ClassificationCancer CellsLeukocytesER (%)Cancer CellsLeukocytesER (%)Cancer cells2024814.2238124.6Cancer cells2024814.2234165.0Cancer cells1727820.2234165.0 | Cancer cells | 184 | 66 | 45.2 | 230 | 20 | 7.0 | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | Leukocytes | 160 | 160 90 45.2 | | 15 235 7.0 | | | |
| Discrimination Based on I_p-t_d Acquired by RPMPredicted Classification by I_p-t_d Actual ClassificationI.0 × PBS0.5 × PBSCancer CellsLeukocytesER (%)Cancer CellsLeukocytesER (%)Cancer CellsLeukocytesER (%)Cancer cells20248Leukocytes23227Cancer cells20248Leukocytes23227Cancer cells112394.6Cancer cells21727820.2234165.0 | Discrimination ER | 45.1 ± 0.3 6.7 ± 0.6 ** | | | | | | |
| Predicted Classification by I_p-t_d Actual Classification1.0 × PBS0.5 × PBSCancer CellsLeukocytesER (%)Cancer CellsLeukocytesER (%)Cancer cells2024814.2238124.6Leukocytes2322714.2112394.6Cancer cells1727820.2234165.0 | Discrimination Based on I_p - t_d Acquired by RPM | | | | | | | |
| Actual Classification $1.0 \times PBS$ $0.5 \times PBS$ Cancer CellsLeukocytesER (%)Cancer CellsLeukocytesER (%)Cancer cells2024814.2238124.6Leukocytes23227112394.6Cancer cells1727820.2234165.0Leukocytes2222720.22345.0 | Actual Classification | Predicted Classification by <i>I</i> _p - <i>t</i> _d | | | | | | |
| Cancer CellsLeukocytesER (%)Cancer CellsLeukocytesER (%)Cancer cells 202 48 14.2 238 12 4.6 Leukocytes 23 227 14.2 11 239 4.6 Cancer cells 172 78 20.2 234 16 5.0 | | $1.0 \times PBS$ | | | 0.5 	imes PBS | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | Cancer Cells | Leukocytes | ER (%) | Cancer Cells | Leukocytes | ER (%) | |
| Leukocytes 23 227 14.2 11 239 4.6 Cancer cells 172 78 20.2 234 16 5.0 | Cancer cells | 202 | 48 | 14.2 | 238 | 12 | 4.6 | |
| Cancer cells 172 78 20.2 234 16 5.0 | Leukocytes | 23 | 227 | | 11 | 239 | | |
| Lo los tos 20 007 20.2 0 041 3.0 | Cancer cells | 172 | 78 | 20.2 | 234 | 16 | 5.0 | |
| Leukocytes 23 227 9 241 | Leukocytes | 23 | 227 | 20.2 | 9 | 241 | | |
| Cancer cells 161 89 21.8 240 10 4.0 | Cancer cells | 161 | 89 | 01.0 | 240 | 10 | 4.0 | |
| Leukocytes 20 230 21.8 10 240 4.0 | Leukocytes | 20 | 230 | 21.8 | 10 | 240 | | |
| Discrimination ER 18.7 ± 4.0 4.5 ± 0.5 ** | Discrimination ER | | 18.7 ± 4.0 | | | 4.5 ± 0.5 ** | | |

Table 1. Cont.

TP: true positive, FN: false negative, FP: false positive, TN: true negative. The CI for the discrimination error rate was evaluated using the Clopper–Pearson method. Significant differences were found in the results under $1.0 \times PBS$ and $0.5 \times PBS$ (** p < 0.01).

3.2. Ionic Current Measurement of Cells

A biased voltage $V_b = 1.0$ V was applied between the inlet and outlet in $1.0 \times PBS$, and the baseline at a current level of approximately 2 µA was measured. The electrical conductivity (σ) of $1.0 \times PBS$ was determined to be 1.41 ± 0.04 S/m. The electric field generated by the bias voltage yields electrophoretic forces to drive the cells and translocate them through the constrictions. As illustrated in Figure 1c, the cells were restricted by a constriction, causing them to pass one by one through the narrow space, which yielded a one-to-one correspondence of a pulse-like signal between the ionic current blockade and a translocation event of a cell through the constriction. Typical waveforms of the current blockades generated by the cancer cells and leukocytes are shown in Figure 3a,b, respectively. The size and deformability of the sensed particles were estimated from the peak height of the current blockade (I_p) generated by the RPM [1,6,7]. As shown in Table 2, the mean values of I_p were significantly different (p < 0.01) for cancer cells and leukocytes (the mean value and SDs were 58.7 ± 1.9 nA and 26.3 ± 1.6 nA, respectively).

| | <i>I</i> _p (| nA) | t _d (ms) | |
|-------------------------|-------------------------|-------------------|---------------------|-------------------|
| | Cancer Cell | Leukocytes | Cancer Cell | Leukocytes |
| $1.0 \times \text{PBS}$ | 58.7 ± 1.9 | $26.3\pm1.6^{**}$ | 145.2 ± 1.9 | 150.0 \pm 1.4 * |
| 0.5 	imes PBS | 50.8 ± 1.6 | $12.0\pm0.2^{**}$ | 136.4 ± 3.8 | 40.7 ± 1.2 ** |

Table 2. Mean of I_p and t_d of each cell by RPM analysis.

Data are expressed as the mean \pm SD for three different experiments. Significantly different from each cell (* *p* < 0.05, ** *p* < 0.01).

Although the difference in I_p between the cancer cells and leukocytes were observed to be larger than that indicated by the results of the cell diameter examination by microscopy, the discrimination error rate based on the detection boundary for I_p (DB_{1p}) was 27.3 \pm 3.5% (Figure 3c, Table 1). Improvement in the accuracy of cell discrimination by I_p could not be observed compared to the microscopic observation. This may have been due to the relatively large variation in the distribution of I_p (Figure 3c). In RPM, the duration time for the current blockade (t_d) can be utilized to elucidate the surface charge of the sensed particles [1,5]. The zeta potential was examined for the estimation of the surface charge of cells. The evaluated zeta potential for cancer cells and leukocytes in $1.0 \times PBS$ were -10.1 ± 0.7 mV and -12.0 ± 0.6 mV (p = 0.048), respectively. As the differences in the zeta potential for cancer cells and leukocytes were confirmed, we further added t_d as the parameter for discrimination. The distribution of t_d is also shown in the t_d histogram in Figure 3c; the mean value and standard deviation of t_d for the cancer cells and leukocytes were 145.2 \pm 1.9 ms and 150.0 \pm 1.4 ms, respectively (Table 2). The discrimination error rate in terms of the detection boundary for t_d (DB_{td}) was calculated to be 45.1 ± 0.3%, and the accurate discrimination could not be estimated by t_d only (Table 1). The I_p-t_d scatter plot was constructed using the measured waveforms for the individual cells, as shown in Figure 3c. By performing discriminant analysis on the I_p-t_d plane, in which the decision boundary was indicated by the broken line as $DB_{Ip}-t_d$, we obtained a discrimination error rate of 18.7 \pm 4.0% (Table 1). The accuracy of discrimination by I_p - t_d showed a significant improvement compared to I_p and t_d (p < 0.01); however, no improvement was observed compared to the microscopic examination.

In $0.5 \times PBS$ ($\sigma = 0.815 \pm 0.005$ S/m), we could apply a bias voltage V_b = 2.0 V to the baseline at a current level of approximately 2 μ A, which is comparable to 1.0 \times PBS. A typical waveform of the ionic current blockade for cancer cells and leukocytes in $0.5 \times PBS$ is shown in Figure 3d,e; the I_p and t_d histograms and I_p-t_d scatter plots are shown in Figure 3f. As shown in Table 2, the mean values of I_p were significantly different (p < 0.01) for cancer cells and leukocytes (the mean value and SDs were 50.8 \pm 1.6 nA and 12.0 \pm 0.2 nA, respectively). The discrimination error rate based on I_p was 4.7 \pm 1.0%; thus, the accuracy was clearly improved compared to the results obtained by the microscopic examination in 0.5 \times PBS (Table 1). The difference in the mean I_p for cancer cells and leukocytes was apparently larger than that of the difference obtained by microscopic examination (Table 2, Figure 2f). The decrease in current, which is denoted by I_p , provides information of not only the particle size/volume, but also the deformability [1,6,7]. In addition to the difference in size between the two cell types, the difference in deformation must be significantly considered. CelSee Diagnostics uses both size exclusion and deformability to capture CTCs. However, a huge number of leukocytes are contaminated as a background in the captured cell population; immunocytochemistry, as well as nucleic acid fluorescence in situ hybridization, are employed for the identification and/or characterization of CTCs [15,30]. Although CTCs cannot be captured by RPM, an accurate discrimination and detection of cancer cells could be obtained by measuring the decrease in current, denoted by *I*_p. The absolute value of the zeta potential decreases in a solution containing a large number of ions because the surface charge is strongly screened by the electrolyte ions [27]. As expected, the zeta potential of the cancer cells and leukocytes was enhanced to -13.5 ± 0.3 mV and -14.6 ± 0.1 mV, respectively, compared to those in $1.0 \times$ PBS. Thereafter, the $t_{\rm d}$ parameter was examined (Figure 3f). The mean value and SD of t_d for the cancer cells and leukocytes

were 136.4 \pm 3.8 ms and 40.7 \pm 1.2 ms, respectively (Table 2). The discrimination error rate in terms of the detection boundary for t_d (DB_{td}) was 6.7 \pm 0.6% (Figure 3f, Table 1). The mean value and SD of t_d for the leukocytes were apparently lower than that in 1.0 \times PBS. This may be attributed to a more accurate measurement of the surface charge of leukocytes through an increase in the electrophoretic force in a solution with a low electrolyte concentration. By performing discriminant analysis on the I_p - t_d plane, in which the decision boundary is indicated by the broken line as DB_{Ip}- t_d , we obtained a discrimination error rate of 4.5 \pm 0.5% (Table 1). The accuracy of discrimination by I_p - t_d indicated a significant improvement over t_d (McNemar test, p < 0.01). There is a tendency to improve the accuracy; however, there is no significant difference between I_p - t_d and I_p . The surface charge of the cells is considered to be less involved in cell discrimination. All I_p , t_d , and I_p - t_d analyses showed a more accurate cell discrimination in 0.5 \times PBS compared to that in 1.0 \times PBS, demonstrating the potential of RPM for an accurate cell discrimination in a solution with a low electrolyte concentration.

We also examined the applicability of RPM to other cell measurements. We showed the I_p-t_d scatter plot by RPM analysis in 0.5 × PBS with a mixture of cancer cells and leukocytes in Figure S1. The results of measuring leukocytes and cancer cells separately and the results of measuring leukocytes and cancer cells in a mixed manner showed quite similar cell distribution results. Furthermore, we showed the I_p-t_d scatter plot by RPM analysis of KATO-III and leukocytes in 0.5 × PBS (Figure S2). Similar cell distribution on I_p-t_d scatter plot to that of NCI-1650 and leukocytes (Figure 3f) was observed, and accurate discrimination by I_p-t_d analysis can be performed. These results show high applicability in other cell measurements.

4. Conclusions

In this study, the size of cancer cells was shown to be significantly larger than that of leukocytes in both the given electrolyte solutions. These results correspond well with those reported in previous studies [31]. The advantages of size-based CTC separation methods from blood include the fact that they are simple, fast, and inexpensive compared to the biological enrichment methods that are based on immunoreactions, including the CellSearch System, which is the only US Food and Drug Administration-approved CTC diagnosis system. However, the overlap in the size of different types of cells may cause a low accuracy. In this study, we demonstrated the potential of a microfluidic cell sensing chip, which is based on the RPM, for an accurate discrimination of cancer cells from leukocytes by measuring multiple parameters such as cell size, deformability, and surface charge in a solution with a low electrolyte concentration.

Supplementary Materials: The following are available online at https://www.mdpi.com/2079-637 4/11/3/78/s1: Figure S1: I_p-t_d scatter plot by RPM analysis in 0.5 × PBS with a mixture of cancer cells and leukocytes. Figure S2: RPM analysis of other cancer cells in 0.5 × PBS. (a) The microscopic images of KATO-III.

Author Contributions: K.Y., M.H., K.K., Y.N. and M.K. designed and conducted the experiments. K.Y., M.T. (Masato Tanaka), S.M., M.T. (Makusu Tsutsui) and M.T. (Masateru Taniguchi) constructed the measurement system and designed the microfluidic cell sensing chip. K.Y. and M.K. wrote the manuscript together. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by JSPS KAKENHI grant number 19H04495.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no competing interest.

References

- 1. Song, Y.X.; Zhang, J.Y.; Li, D.Q. Microfluidic and nanofluidic resistive pulse sensing: A review. *Micromachines* **2017**, *8*, 204. [CrossRef]
- Tsutsui, M.; Yoshida, T.; Yokota, K.; Yasaki, H.; Yasui, T.; Arima, A.; Tonomura, W.; Nagashima, K.; Yanagida, T.; Kaji, N.; et al. Discriminating single-bacterial shape using low-aspect-ratio pores. *Sci. Rep.* 2017, *7*, 17371. [CrossRef] [PubMed]
- Yusko, E.C.; Bruhn, B.R.; Eggenberger, O.M.; Houghtaling, J.; Rollings, R.C.; Walsh, N.C.; Nandivada, S.; Pindrus, M.; Hall, A.R.; Sept, D.; et al. Real-time shape approximation and fingerprinting of single proteins using a nanopore. *Nat. Nanotechnol.* 2017, 12, 360–367. [CrossRef] [PubMed]
- Ryuzaki, S.; Tsutsui, M.; He, Y.; Yokota, K.; Arima, A.; Morokawa, T.; Taniguchi, M.; Kawai, T. Rapid structural analysis of nanomaterials in aqueous solutions. *Nanotechnology* 2017, 28, 155501. [CrossRef]
- 5. Arjmandi, N.; Van Roy, W.; Lagae, L.; Borghs, G. Measuring the electric charge and zeta potential of nanometer-sized objects using pyramidal-shaped nanopores. *Anal. Chem.* **2012**, *84*, 8490–8496. [CrossRef] [PubMed]
- Zheng, Y.; Nguyen, J.; Wang, C.; Sun, Y. Electrical measurement of red blood cell deformability on a microfluidic device. *Lab Chip* 2013, 13, 3275–3283. [CrossRef] [PubMed]
- Darvish, A.; Goyal, G.; Aneja, R.; Sundaram, R.V.K.; Lee, K.; Ahn, C.W.; Kim, K.-B.; Vlahovska, P.M.; Kim, M.J. Nanoparticle mechanics: Deformation detection via nanopore resistive pulse sensing. *Nanoscale* 2016, *8*, 14420–14431. [CrossRef]
- Luo, L.; German, S.R.; Lan, W.-J.; Holden, D.A.; Mega, T.L.; White, H.S. Resistive-pulse analysis of nanoparticles. *Annu. Rev. Anal. Chem.* 2014, 7, 513–535. [CrossRef] [PubMed]
- 9. Wanunu, M. Nanopores: A journey towards DNA sequencing. *Phys. Life Rev.* 2012, 9, 125–158. [CrossRef]
- 10. Howorka, S.; Siwy, Z. Nanopore analytics: Sensing of single molecules. *Chem. Soc. Rev.* 2009, 38, 2360–2384. [CrossRef] [PubMed]
- Xu, Y.; Xie, X.; Duan, Y.; Wang, L.; Cheng, Z.; Cheng, J. A review of impedance measurements of whole cells. *Biosens. Bioelectron.* 2016, 77, 824–836. [CrossRef]
- 12. Fidler, I.J. Timeline—The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. *Nat. Rev. Cancer* 2003, *3*, 453–458. [CrossRef] [PubMed]
- Sieuwerts, A.M.; Kraan, J.; Bolt, J.; van der Spoel, P.; Elistrodt, F.; Schutte, M.; Martens, J.W.M.; Gratama, J.-W.; Sleijfer, S.; Foekens, J.A. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. *J. Natl. Cancer Inst.* 2009, 101, 61–66. [CrossRef]
- Mostert, B.; Kraan, J.; Bolt-de Vries, J.; van der Spoel, P.; Sieuwerts, A.M.; Schutte, M.; Timmermans, A.M.; Foekens, R.; Martens, J.W.M.; Gratama, J.-W. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res. Treat. 2011, 127, 33–41. [CrossRef] [PubMed]
- 15. van der Toom, E.E.; Verdone, J.E.; Gorin, M.A.; Pienta, K.J. Technical challenges in the isolation and analysis of circulating tumor cells. *Oncotarget* **2016**, *7*, 62754–62766. [CrossRef] [PubMed]
- 16. Tsutsui, M.; He, Y.; Furuhashi, M.; Rahong, S.; Taniguchi, M.; Kawai, T. Transverse electric field dragging of DNA in a nanochannel. *Sci. Rep.* **2012**, *2*, 394. [CrossRef] [PubMed]
- 17. Sibarani, J.; Takai, M.; Ishihara, K. Surface modification on microfluidic devices with 2-methacryloyloxyethyl phosphorylcholine polymers for reducing unfavorable protein adsorption. *Colloids Surf. B. Biointerfaces* **2007**, *54*, 88–93. [CrossRef] [PubMed]
- 18. Fukazawa, K.; Ishihara, K. Simple surface treatment using amphiphilic phospholipid polymers to obtain wetting and lubricity on polydimethylsiloxane-based substrates. *Colloids Surf B Biointerfaces* **2012**, *97*, 70–76. [CrossRef] [PubMed]
- 19. Pischel, D.; Buchbinder, J.H.; Sundmacher, K.; Lavrik, I.N.; Flassig, R.J. A guide to automated apoptosis detection: How to make sense of imaging flow cytometry data. *PLoS ONE* **2018**, *13*, e0197208. [CrossRef]
- 20. Fraley, C.; Raftery, A.E. Model-based clustering, discriminant analysis, and density estimation. J. Am. Stat. Assoc. 2002, 97, 611–631. [CrossRef]
- 21. Wernecke, K.-D. Discriminant Analysis. In *Wiley Encyclopedia of Clinical Trials*; D'Agostino, R.B., Sullivan, L., Massaro, J., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2007; pp. 1–19.
- 22. Ballabio, D.; Todeschini, R. Multivariate Classification for Quantitative Analysis. In *Infrared Spectroscopy for Food Quality Analysis* and Control, 1st ed.; Sun, D.-W., Ed.; Elsevier: London, UK, 2009; pp. 83–104.
- Fagerland, M.W.; Lydersen, S.; Laake, P. Recommended tests and confidence intervals for paired binomial proportions. *Stat. Med.* 2014, 33, 2850–2875. [CrossRef] [PubMed]
- 24. Smeets, R.M.; Keyser, U.F.; Dekker, N.H.; Dekker, C. Noise in solid-state nanopores. *Proc. Natl. Acad. Sci. USA* 2008, 105, 417–421. [CrossRef] [PubMed]
- 25. Bondar, O.V.; Saifullina, D.V.; Shakhmaeva, I.I.; Mavlyutova, I.I.; Abdullin, T.I. Monitoring of the zeta potential of human cells upon reduction in their viability and interaction with polymers. *Acta Nat.* **2012**, *4*, 78–81. [CrossRef]
- Dobrzynska, I.; Skrzydlewska, E.; Figaszewski, Z.A. Changes in electric properties of human breast cancer cells. J. Membr. Biol. 2013, 246, 161–166. [CrossRef]
- 27. Schoch, R.B.; Han, J.Y.; Renaud, P. Transport phenomena in nanofluidics. Rev. Mod. Phys. 2008, 80, 839–883. [CrossRef]
- 28. de Wit, S.; van Dalum, G.; Lenferink, A.T.M.; Tibbe, A.G.J.; Hiltermann, T.J.N.; Groen, H.J.M.; van Rijn, C.J.M.; Terstappen, L. The detection of EpCAM⁺ and EpCAM⁻ circulating tumor cells. *Sci. Rep.* **2015**, *5*, 12270. [CrossRef]
- 29. Rostami, P.; Kashaninejad, N.; Moshksayan, K.; Saidi, M.S.; Firoozabadi, B.; Nguyen, N.T. Novel approaches in cancer management with circulating tumor cell clusters. *J. Sci. Adv. Mater. Dev.* **2019**, *4*, 1–18. [CrossRef]

- 30. Gogoi, P.; Sepehri, S.; Zhou, Y.; Gorin, M.A.; Paolillo, C.; Capoluongo, E.; Gleason, K.; Payne, A.; Boniface, B.; Cristofanilli, M.; et al. Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. *PLoS ONE* **2016**, *11*, e0147400. [CrossRef]
- 31. Austin, R.G.; Huang, T.J.; Wu, M.; Armstrong, A.J.; Zhang, T. Clinical utility of non-EpCAM based circulating tumor cell assays. *Adv. Drug Deliv. Rev.* **2018**, *125*, 132–142. [CrossRef] [PubMed]